Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 485.00 GBp
Change Today 0.00 / 0.00%
Volume 1.2K
IVO On Other Exchanges
Symbol
Exchange
London
Berlin
As of 11:35 AM 07/31/15 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

Julian Mathew Smith

Former Chief Financial Officer, Chief Operations Officer, Executive Director and Member of Investment Committee, Imperial Innovations Group plc
AgeTotal Calculated CompensationThis person is connected to 7 board members in 1 different organizations across 4 different industries.

See Board Relationships
50224,000 GBP
As of Fiscal Year 2014

Background*

Mr. Julian Smith has been the Chief Financial Officer of Abzena plc since September 09, 2013 and serves as its Secretary. Mr. Smith has been the Chief Operating Officer of Antitope Ltd. since September 2013. He served as the Chief Operations Officer and Chief Financial Officer at Cortexica Vision Systems Limited since January 2006. Mr. Smith served as the Chief Financial and Operating Officer of Imperial Innovations Group plc from January 3, 2006 to April 2013. He spent ...

Read Full Background

Corporate Headquarters*

52 Princes Gate
London, Greater London SW7 2PG

United Kingdom

Phone: 44 20 7581 4949
Fax: 44 20 7589 8987

Board Members Memberships*

2013-Present
Chief Financial Officer, Company Secretary and Executive Director

Education*

MA
University of Oxford

Other Affiliations*

Annual Compensation*

Salary192,000 GBP
Bonus18,000 GBP
Total Annual Compensation210,000 GBP

Stock Options*

All Other Compensation14,000 GBP
Exercised Options251,700
Total Value of Options782,678 GBP
Total Number of Options1,192,985

Total Compensation*

Total Annual Cash Compensation224,000 GBP
Total Short Term Compensation210,000 GBP
Other Long Term Compensation14,000 GBP
Total Calculated Compensation224,000 GBP
*Data is at least as current as the most recent Definitive Proxy.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IVO:LN 485.00 GBp 0.00

COMPETITOR COMPENSATION

NamePosition/
Company
Compensation
Daniel M. Junius Chief Executive Officer, President and Director
ImmunoGen, Inc.
$544.5K
Howard W. Robin Chief Executive Officer, President and Director
Nektar Therapeutics
$860.0K
Judith Greciet Ph.D., PharmacyChief Executive Officer, Director and Member of Corporate Development Committee
Onxeo SA
€424.3K
William J. Polvino M.D.Chief Executive Officer and President
Veloxis Pharmaceuticals A/S
--
Daniel J. Abdun-Nabi Chief Executive Officer, President, Director, Member of Strategic Operations Committee and Member of Pricing Committee
Emergent BioSolutions, Inc.
$1.2M
Compensation as of Fiscal Year 2014.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact IMPERIAL INNOVATIONS GROUP P, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.